{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:29:29Z","timestamp":1791354569083,"version":"4.3.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To determine whether treatment with guanfacine extended release (GXR) in subjects with attention-deficit\/hyperactivity disorder (ADHD) disrupted psychomotor functioning and alertness, or impacted daytime sleepiness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This was a randomized, double-blind, placebo-controlled, multicenter, phase 2, dose-optimization, noninferiority, laboratory classroom study of GXR (1, 2, and 3\u2009mg\/day) in 182 subjects aged 6 to 17 years with ADHD. Psychomotor functioning and alertness were assessed through several measures, including the Choice Reaction Time (CRT) test from the Cambridge Neuropsychological Test Automated Battery. Sedative effects were examined via spontaneously reported adverse events of sedation, somnolence, and hypersomnia as well as fatigue and lethargy, and with two validated subject- and observer-rated sleepiness scales. Standard efficacy measures for ADHD also were included. Cardiovascular and laboratory parameters were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were no significant differences between the GXR and placebo groups on measures of psychomotor functioning or alertness from the CRT at endpoint (least-square mean difference: 2.5 [95% confidence interval (CI): \u221222.9, 28.0],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.8 for CRT; 2.5 [95% CI: \u221221.5, 26.4],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.84 for correct responses; 15.5 [95% CI: \u221245.1, 14.1],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.30 for movement time; and \u22128.2 [95% CI: \u221254.1, 37.6]\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.72 for total time). Most sedative adverse events were mild to moderate, occurred during dose titration, decreased with dose maintenance, and resolved during the study period. One subject in the GXR group discontinued due to fatigue and somnolence. GXR was not associated with increased daytime sleepiness. GXR treatment was associated with significant improvement in ADHD symptoms (6.3 [95% CI: 2.7, 9.8],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001 for ADHD Rating Scale IV total scores at endpoint).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>At doses that resulted in significant improvement in ADHD symptoms, impairment on cognitive tasks was not observed. Daytime sleepiness did not differ with GXR compared with placebo. Results suggest that the beneficial effects of GXR on ADHD symptoms are independent of sedation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2010.0064","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T15:04:04Z","timestamp":1303225444000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":45,"title":["Psychomotor Functioning and Alertness with Guanfacine Extended Release in Subjects with Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1177","volume":"21","author":[{"given":"Scott H.","family":"Kollins","sequence":"first","affiliation":[{"name":"Duke University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Children's Developmental Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Vince","sequence":"additional","affiliation":[{"name":"Vince and Associates Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Turnbow","sequence":"additional","affiliation":[{"name":"Westex Clinical Investigations"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Farrand","sequence":"additional","affiliation":[{"name":"Shire Development Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lyne","sequence":"additional","affiliation":[{"name":"Shire Pharmaceutical Development Ltd","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon B.","family":"Wigal","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roth","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital Sleep Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,4,1]]},"reference":[{"key":"e_1_3_2_2_1","volume-title":"Diagnostic, and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic, and Statistical Manual of Mental Disorders, 4thText Revision (DSM-IV-TR)Washington, DC: American Psychiatric Association, 2000.","edition":"4"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0098"},{"key":"e_1_3_2_4_1","first-page":"S22","article-title":"The emerging neurobiology of attention deficit hyperactivity disorder: The key role of the prefrontal association cortex","volume":"154","author":"Arnsten AFT","year":"2009","unstructured":"Arnsten AFT. The emerging neurobiology of attention deficit hyperactivity disorder: The key role of the prefrontal association cortex. J Pediatr, 154:S22\u2013S31. 2009.","journal-title":"J Pediatr"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200403000-00006"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.015"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.2.258"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3695"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.986"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.12.030"},{"key":"e_1_3_2_11_1","first-page":"455","article-title":"The pediatric daytime sleepiness scale (PDSS): Sleep habits and school outcomes in middle-school children","volume":"26","author":"Drake C","year":"2003","unstructured":"Drake C, , Nickel C, , Burduvali E, , Roth T, , Jefferson C, , Pietro B. The pediatric daytime sleepiness scale (PDSS): Sleep habits and school outcomes in middle-school children. Sleep, 26:455\u2013458. 2003.","journal-title":"Sleep"},{"key":"e_1_3_2_12_1","volume-title":"ADHD Rating Scale-IV: Checklists, Norms, Clinical Interpretation","author":"DuPaul GJ","year":"1998","unstructured":"DuPaul GJ, , Power TJ, , Anastopoulos AD, , Reid R. ADHD Rating Scale-IV: Checklists, Norms, Clinical Interpretation. New York, NY: Guilford Press, 1998."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.859"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-19-08771.2002"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-005-3291-4"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0278-2626(90)90047-R"},{"key":"e_1_3_2_17_1","unstructured":"Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville MD: US Department of Health Education and Welfare; Public Health Service Alcohol Drug Abuse and Mental Health Administration NIMH Psychopharmacology Research Branch 1976; 218\u2013222."},{"key":"e_1_3_2_18_1","unstructured":"Intuniv [package insert]. Wayne PA: Shire Pharmaceuticals Inc. 2009."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799008338"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2005.11.002"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.3.541"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530540-000000000-00000"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2004.00221.x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.11.1896"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2007.05148.x"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/30.12.1698"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207458508985597"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90299-6"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.01.017"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-3-17"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054705286049"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.4.883"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2010.0064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2010.0064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2010.0064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:00Z","timestamp":1777388100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2010.0064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1089\/cap.2010.0064"],"URL":"https:\/\/doi.org\/10.1089\/cap.2010.0064","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}